HUTCHMED (NASDAQ:HCM - Get Free Report) was downgraded by Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued on Saturday.
Separately, HSBC lowered HUTCHMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th.
Read Our Latest Stock Analysis on HCM
HUTCHMED Price Performance
NASDAQ:HCM traded down $1.08 during trading hours on Friday, hitting $15.71. The company's stock had a trading volume of 65,418 shares, compared to its average volume of 99,951. The stock has a fifty day simple moving average of $14.51 and a 200-day simple moving average of $14.73. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.70 and a current ratio of 2.83. HUTCHMED has a twelve month low of $11.51 and a twelve month high of $21.50.
Institutional Trading of HUTCHMED
Hedge funds have recently made changes to their positions in the company. Barclays PLC boosted its stake in shares of HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after purchasing an additional 2,255 shares in the last quarter. Public Employees Retirement System of Ohio boosted its stake in shares of HUTCHMED by 49.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock valued at $39,000 after purchasing an additional 899 shares in the last quarter. Summit Trail Advisors LLC boosted its stake in shares of HUTCHMED by 7.7% during the first quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock valued at $212,000 after purchasing an additional 1,004 shares in the last quarter. OLD Mission Capital LLC acquired a new stake in shares of HUTCHMED during the fourth quarter valued at about $230,000. Finally, Marshall Wace LLP acquired a new stake in shares of HUTCHMED during the fourth quarter valued at about $261,000. 8.82% of the stock is owned by institutional investors and hedge funds.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
